All In Biotech

Drug Trial Radar · NCT07450976

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

151

Planned (sponsor's estimate)

Start

Mar 25, 2026

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.

Conditions

  • Biliary Tract Cancer

Interventions

  • SHR-A1904 for InjectionDrug

    SHR-A1904 for injection, different doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) assessed by investigator.Time frame: Until progression, assessed up to approximately 1 year.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.